Brainstorm Cell Therapeutics Inc.

Greetings, everyone, and welcome to the Brainstorm Cell Therapeutics financial results for the second quarter of 2020 and corporate update conference call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star and zero on your telephone keypads. As a reminder, today's conference call is being recorded. It is now my pleasure to introduce your host, Michael Wood of LifeSciAdvisors. Sir, you may begin.

Thank you, operator, and thank you all for joining the Brainstorm Cell Therapeutics Call today. Before we begin the opening remarks, I'd like to remind listeners that this conference call contains numerous statements, descriptions, forecasts, and projections regarding Brainstorm Cell Therapeutics and its future business operations and performance. Statements regarding the market potential for the treatment of neurodegenerative disorders such as ALS and MS, the sufficiency of the company's existing capital resources for continuing operations in 2020 and beyond, the safety and clinical effectiveness of neuro and technology platform, clinical trials of neuron and related clinical development programs, as well as the ability of the company to develop strategic collaborations and partnerships to support the business planning efforts. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond the company's control, including the risks and uncertainties described from time to time in its SEC filings. Results may differ materially from those projected on today's call. The company undertakes no obligation to publicly update any forward-looking statements. Joining me on the call today will be Hein Liebowitz, CEO of Brainstorm, Dr. Ralph Curran, President and Chief Medical Officer, Dr. Revital Arisha, VP of Research and Development, and Dr. Pritam Shah, EVP and Chief Financial Officer. They will be available to answer questions, as well as with additional members of the management team during the Q&A session, which follows the prepared remarks. So, now I'd like to turn the call over to Mr. Leibowitz. At that time, please go ahead.

Thank you, Mike. Welcome to Brainstorm's second quarter 2020 earnings call, and thank you, everyone, for joining us. At the onset of this call, I'm so proud to share with you that our cash on hand is by far a record for Brainstorm. We have never been in such a strong financial position. We have no debt, no convertibles, or the like. We today have close to $35 million cash on hand. I'll begin this morning's call with some introductory remarks and general corporate updates at Brainstorm. Next, our President and Chief Medical Officer, Dr. Ralph Kern, will update you on our clinical programs, including our pivotal ALS trial, a recently announced phase two Alzheimer's disease program and our phase two progressive MS trial. Following Ralph's comments, Dr. Ravital Arija, our VP R&D, will walk you through our development program for neuron-derived exosome treatment for COVID-19 ARDS. Our chief financial officer, Dr. Pridham Shah, will then provide updates on our financial results before turning it back to me for concluding remarks. We will, of course, address your questions in the Q&A session. We are proud of the continued dedication and focus from our team members during these challenging times of the coronavirus pandemic. Our mission at Brainstorm is to leverage our proprietary neuron technology into the clinical development of new treatments for neurodegenerative disease patients with high unmet medical needs. This is an extremely important and worthy mission during normal times. and it requires an even greater level of commitment, creativity, and collaboration with them. We are grateful to our community partners, which includes patients, their families, doctors, regulatory bodies, and so many more for helping us to continue to move forward over the past few months. This morning, I would like to also recognize two new addition to our senior management team in the second quarter, Dr. Seved Sedman, joined us in April 2020 and serves as Executive Vice President and Chief Operating Officer. Dr. Sedbon has extensive experience in the biopharmaceutical industry, including key leadership roles in commercial development and product launches at Biogen. Most recently he served as VP Corporate Development Strategy and Business at Life Biosciences where he was instrumental in the development of various critical commercial operating and funding milestones. We are thrilled that David has joined our team and expect him to play a key role in the potential commercial launch of Neuron in the next couple of years. Dr. Stacey Lindbergh joined us in June 2020 in the role of Executive Vice President and Head of Global Clinical Research. Dr. Lindbergh is an experienced healthcare executive and globally recognized medical statistician with over two decades of multinational experience in R&D, regulatory strategies development, analytics, and big data at Lilly and Biogen. Most recently, Dr. Lindbergh spent eight years at Biogen, where she held several leadership positions, including vice president of analytics and data science. Stacy is a great addition to our team, and her deep experience will be highly valued in many areas at Brainstorm. I will now turn the call over to Dr. Ralph Kern, who will provide updates on our major clinical development programs. Ralph?